A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas and Other Non-small Cell Lung Cancer
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Savolitinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
- 01 Aug 2022 According to an AstraZeneca media release, final overall survival data presented at ELCC22 2022.
- 11 May 2022 Results assessing patient-level data from the VISION study and comparison with GEOMETRY mono-1 (capmatinib), NCT02897479 (savolitinib) and PROFILE 1001 (crizotinib) studies in patients with advanced NSCLC published in the Advances in Therapy
- 29 Nov 2021 Planned primary completion date changed from 30 Sep 2021 to 30 Dec 2021.